Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
IGFBP7 encodes a member of the insulin-like growth factor (IGF)-binding protein (IGFBP) family. Additionally we are shipping Insulin-Like Growth Factor Binding Protein 7 Kits (31) and Insulin-Like Growth Factor Binding Protein 7 Proteins (19) and many more products for this protein.
Showing 10 out of 115 products:
Human Monoclonal IGFBP7 Primary Antibody for IHC, ELISA - ABIN1724903
Abu-Safieh, Abboud, Alkuraya, Shamseldin, Al-Enzi, Al-Abdi, Hashem, Colak, Jarallah, Ahmad, Bobis, Nemer, Bitar, Alkuraya: Mutation of IGFBP7 causes upregulation of BRAF/MEK/ERK pathway and familial retinal arterial macroaneurysms. in American journal of human genetics 2011
Show all 2 references for ABIN1724903
Human Monoclonal IGFBP7 Primary Antibody for ELISA, WB - ABIN1724902
Evdokimova, Tognon, Benatar, Yang, Krutikov, Pollak, Sorensen, Seth: IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. in Science signaling 2012
Show all 2 references for ABIN1724902
Cow (Bovine) Polyclonal IGFBP7 Primary Antibody for ELISA - ABIN409083
Ruan, Xu, Xu, Ma, Deng, Huang, Lv, Hu, Lin, Cui, Di, Dong, Lai: IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. in Cancer biology & therapy 2007
Cow (Bovine) Polyclonal IGFBP7 Primary Antibody for WB - ABIN2773913
Wajapeyee, Serra, Zhu, Mahalingam, Green: Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. in Cell 2008
Human Polyclonal IGFBP7 Primary Antibody for EIA, WB - ABIN498022
Evans, Johnson, Laurenson, Davies, Ko Ferrigno, Wälti: Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays. in Journal of biology 2008
Insulin-like growth factor binding protein 7 (IGFBP7) was proven to be associated with metastatic clinicopathological features and high lymphatic vascular density
data suggest that TGF-beta1 (show TGFB1 Antibodies) enhances IGFBP7 via Smad2 (show SMAD2 Antibodies)/4 pathways, and that IGFBP7 might be involved in the TGF-beta1 (show TGFB1 Antibodies)-induced tubular injury in DN.
This study shows that urinary [TIMP-2 (show TIMP2 Antibodies)]*[IGFBP7] has a good diagnostic performance in predicting adverse outcomes in neonatal and pediatric AKI of heterogeneous etiology.
Inhibition of IGF1 (show IGF1 Antibodies)-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL
serum IGFBP7 levels are associated with IR and MetS (show ETV3 Antibodies), providing new insight into the mechanism of IR and Mets (show ETV3 Antibodies). IGFBP7 may be a potential interventional target for IR and Mets (show ETV3 Antibodies).
IGFBP-7 can alter EMT (show ITK Antibodies) relative marker genes and suppress cell invasion in A253 cell through AKT (show AKT1 Antibodies)/GSK3beta (show GSK3b Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling.
IGFBP7 down-regulation is associated with poor prognosis in glioma, and this molecule may represent both a prognostic marker and a potential therapeutic target.
Our data indicate that IGFBP7 expression is a marker for a specific methylation pattern in myeloma
The low levels of IGFBP7 in high-grade serous ovarian carcinoma are associated with survival rate.
Overexpression of IGFBP7 was associated with tumour progression and poor survival in gastric cancer. IGFBP7 may play a role in tumour progression in gastric cancer.
data suggest that IGFBP-7 was up regulated during EAE and inhibit the transition from OPCs to mature OLs, implying its use as a potential therapeutic target for the treatment of inflammatory demyelinating diseases
Our data suggest that loss of Igfbp7 induces precocious involution possibly through diminished cell survival signals.
Angiomodulin is necessary for cardiac commitment of embryonic stem cells (ESCs (show NR2E3 Antibodies)) and its regulation depends on TAp63 isoform.
results show that Smarcb1 (show SMARCB1 Antibodies) is required for transcriptional activation of Igfbp7 and show that re-introduction of Igfbp7 alone can hinder tumor development; results define a novel mechanism for Smarcb1 (show SMARCB1 Antibodies)-mediated tumorigenesis
a model whereby IGFBP7 binds to unoccupied IGF1R (show IGF1R Antibodies) and suppresses downstream signaling, thereby inhibiting protein synthesis, cell growth, and survival.
IGFBP7 has a novel role in mouse uterus: it is regulating uterine receptivity through Th1 (show HAND1 Antibodies)/Th2 lymphocyte balance and decidualization.
fear extinction-induced IGF2/IGFBP7 signalling promotes the survival of 17-19-day-old newborn hippocampal neurons
Results demonstrate that the vascular-specific marker angiomodulin (AGM) modulates vascular remodeling in part by temporizing the proangiogenic effects of VEGF-A (show VEGFA Antibodies).
study showed that IGFBP-rP1 (IGFBP7) was expressed in dysregulated podocytes in a human immunodeficiency virus-associated nephropathy model and in immature podocytes in the developing kidney; conclude that IGFBP-rP1 may be a product of injured podocytes
inhibition of Malignant melanoma growth is due to apoptosis and reduced expression of VEGF (show VEGFA Antibodies) induced by pEGFC1-IGFBP7
This gene encodes a member of the insulin-like growth factor (IGF)-binding protein (IGFBP) family. IGFBPs bind IGFs with high affinity, and regulate IGF availability in body fluids and tissues and modulate IGF binding to its receptors. This protein binds IGF-I and IGF-II with relatively low affinity, and belongs to a subfamily of low-affinity IGFBPs. It also stimulates prostacyclin production and cell adhesion. Alternatively spliced transcript variants encoding different isoforms have been described for this gene, and one variant has been associated with retinal arterial macroaneurysm (PMID:21835307).
insulin-like growth factor-binding protein 7
, IGF-binding protein 7
, PGI2-stimulating factor
, prostacyclin-stimulating factor
, tumor-derived adhesion factor